Literature DB >> 11699227

Clinical characteristics of familial B-CLL in the National Cancer Institute Familial Registry.

N Ishibe1, M T Sgambati, L Fontaine, L R Goldin, N Jain, N Weissman, G E Marti, N E Caporaso.   

Abstract

In an ongoing study, families with two or more living cases of B-CLL in first-degree relatives have been recruited through physician and self-referral. Since 1967, 28 kindreds with 73 cases of B-CLL have been enrolled within the National Cancer Institute (NCI) Familial B-CLL Registry. Medical, clinical, and demographic information have been obtained from private physicians, patient interview, hospital records, and death certificates. We used SEER Registry data to compare characteristics of sporadic B-CLL to familial B-CLL. The mean age at diagnosis was approximately 10 years younger among familial cases (57.9 +/- 12.1) than that observed in sporadic cases (70.1 +/- 11.9). A higher percentage of second primary tumors among familial CLL cases compared to reports in sporadic was also observed (16% vs. 8.8%). However, the transformation rate to non-Hodgkin's lymphoma does not appear to be different from that reported for sporadic cases. In conclusion, we observed some differences between familial and sporadic cases; whether any of these characteristics affect survival time or severity of disease is unknown. The study of families with multiple B-CLL cases will aid in delineating the genes and environmental factors that may play a role in the development of both forms of B-CLL.

Entities:  

Mesh:

Year:  2001        PMID: 11699227     DOI: 10.3109/10428190109097681

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  18 in total

1.  Familial Aspects of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and Related Lymphomas.

Authors:  Lynn R Goldin; Ola Landgren; Gerald E Marti; Neil E Caporaso
Journal:  European J Clin Med Oncol       Date:  2010-02

2.  Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia.

Authors:  Lynn R Goldin; Magnus Björkholm; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

Review 3.  How I treat CLL up front.

Authors:  John G Gribben
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

Review 4.  Familial chronic lymphocytic leukemia.

Authors:  Lynn R Goldin; Susan L Slager; Neil E Caporaso
Journal:  Curr Opin Hematol       Date:  2010-07       Impact factor: 3.284

5.  Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization.

Authors:  Sunita R Setlur; Chunhwa Ihm; Joelle Tchinda; Soheil Shams; Lillian Werner; Eun Kyung Cho; Christina Thompson; Kimberly Phillips; Laura Z Rassenti; Thomas J Kipps; Donna Neuberg; Arnold S Freedman; Charles Lee; Jennifer R Brown
Journal:  Br J Haematol       Date:  2010-08-31       Impact factor: 6.998

Review 6.  Familial chronic lymphocytic leukemia.

Authors:  Richard S Houlston; Daniel Catovsky
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

7.  Combined somatic mutation and copy number analysis in the survival of familial CLL.

Authors:  Weiyin Zhou; Lynn Goldin; Mingyi Wang; Mary L McMaster; Kristine Jones; Laurie Burdett; Stephen J Chanock; Meredith Yeager; Michael Dean; Neil E Caporaso
Journal:  Br J Haematol       Date:  2018-04-24       Impact factor: 6.998

Review 8.  Familial leukemias.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2015-02

Review 9.  Familial chronic lymphocytic leukemia: what does it mean to me?

Authors:  Susan L Slager; Neil E Kay
Journal:  Clin Lymphoma Myeloma       Date:  2009

10.  Common genetic variants in candidate genes and risk of familial lymphoid malignancies.

Authors:  Xueying Sharon Liang; Neil Caporaso; Mary Lou McMaster; David Ng; Ola Landgren; Meredith Yeager; Stephen Chanock; Lynn R Goldin
Journal:  Br J Haematol       Date:  2009-07-01       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.